Lead Product(s) : Dolcanatide
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SP-333 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 13, 2013
Lead Product(s) : Dolcanatide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolcanatide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SP-333 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Occupational Exposure.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 12, 2012
Lead Product(s) : Dolcanatide
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable